Merck cuts ties to Moderna’s early-phase KRAS vaccine, leaving mRNA specialist to mull next stepsnews2022-02-24T13:52:04+00:00February 24th, 2022|FierceBiotech|
Amicus’ gene therapy SPAC merger folds, turning pipeline and R&D into target of $400M in cutsnews2022-02-24T12:51:06+00:00February 24th, 2022|FierceBiotech|
Mnemo lures Bayer oncology business chief as new CEO to lead CAR-T worknews2022-02-23T15:31:01+00:00February 23rd, 2022|FierceBiotech|
Kodiak’s Eylea rival hits ‘major disappointment’ with failure in first of 6 phase 3 studiesnews2022-02-23T14:04:38+00:00February 23rd, 2022|FierceBiotech|
Sanofi, GSK post 58% efficacy in omicron-affected COVID-19 vaccine trial, teeing up race to regulatorsnews2022-02-23T12:39:31+00:00February 23rd, 2022|FierceBiotech|
Stability woes torpedo Marinus’ phase 3 seizure timeline, combining with COVID-19 to cause one-year delaynews2022-02-23T10:04:26+00:00February 23rd, 2022|FierceBiotech|
Roche’s gene therapy unit finds a new Spark as co-founding CEO makes way for new leadernews2022-02-23T04:45:33+00:00February 23rd, 2022|FierceBiotech|
‘Better than Abecma’: Slimmed-down 2seventy charts own course after bluebird splitnews2022-02-22T23:34:11+00:00February 22nd, 2022|FierceBiotech|
Poseida taps former Novartis VP as president of gene therapynews2022-02-22T20:09:13+00:00February 22nd, 2022|FierceBiotech|
Plexium nabs $102M for protein degradation work weeks after $500M Amgen tie-upnews2022-02-22T16:44:45+00:00February 22nd, 2022|FierceBiotech|
